--- title: 'Principal Scientist, Analytical Development, Oligo and Small Molecule at Praxis Precision Medicines, Inc.' canonical: 'https://feeny.ai/job/principal-scientist-analytical-development-oligo-and-small-molecule-praxis-nkyv488s0d6s' type: 'job' last_seen: '2026-09-06' --- # Principal Scientist, Analytical Development, Oligo and Small Molecule at Praxis Precision Medicines, Inc. - **Company:** Praxis Precision Medicines, Inc. - **Location:** United States - **Compensation:** $165k–$185k - **Work type:** remote - **Posted:** 2026-01-21 - **Last confirmed live:** 2026-09-06 - **Apply:** https://job-boards.greenhouse.io/praxisprecisionmedicines/jobs/5060288008 ## Job description Location:  This position may be performed remotely, but requires the flexibility and willingness to travel as needed. Position Summary - The Principal Scientist, Analytical Development will play a critical role in advancing Praxis’ clinical and commercial pipeline by translating analytical strategies from development into manufacturing across our virtual network of CMOs and external partners. - This role is particularly focused on advancing oligonucleotide-based therapeutics, while also supporting small molecule programs across the portfolio. The individual will bring deep expertise in analytical method development, qualification, validation, troubleshooting, and GMP testing for oligonucleotide drug substances and drug products, with the ability to apply phase-appropriate analytical strategies across multiple modalities. - This is a highly cross-functional, hands-on leadership role requiring close partnership with Drug Substance, Drug Product, Quality, Regulatory, and Manufacturing teams to ensure robust, scalable, and compliant analytical control strategies. The successful candidate will help shape an agile, forward-looking analytical development function capable of supporting innovative CNS therapies from early development through commercialization. Primary Responsibilities - Serve as Analytical Lead across CMC programs, with primary responsibility for oligonucleotide analytical development activities and support for small molecule programs - Lead analytical method development, qualification, validation, transfer, and GMP testing activities across internal teams and external partners - Drive technical troubleshooting, data interpretation, method lifecycle management, and review of analytical documentation including validation reports, stability reports, specifications, and CoAs - Design and implement phase-appropriate analytical control strategies, specifications, and stability programs for oligonucleotide and small molecule drug substances and drug products - Direct and manage CRO/CMO analytical partners to ensure high-quality execution, strong communication, and continuous operational improvement - Collaborate cross-functionally to strengthen CMC operations, improve processes, and establish scalable technical and business practices across the analytical function - Contribute strategic and technical expertise to support regulatory filings, commercialization readiness, and ongoing product lifecycle management ## Qualifications and Key Success Factors - Advanced degree (PhD preferred; Master’s with significant industry experience considered) in Analytical Chemistry or related discipline with 5–7+ years of industry experience - Strong industry experience in analytical development for oligonucleotide drug substances and/or drug products required - Experience supporting small molecule drug substances and solid oral dosage forms strongly preferred - Deep knowledge of analytical techniques relevant to oligonucleotides, including impurity characterization, stability assessment, and GMP control strategies - Strong understanding of US and EU cGMP requirements and analytical best practices for drug substance and drug product development - Experience supporting CMC development across multiple stages of development, including regulatory submissions, validation, and commercialization activities - Experience managing external CRO/CMO analytical networks and building productive technical partnerships - Strong working knowledge of quality systems, reference standards, stability programs, and compendial testing requirements ## Key Success Factors - Brings deep technical curiosity and strong scientific judgment, particularly in emerging oligonucleotide modalities - Operates with high ownership and accountability in fast-moving, ambiguous environments - Balances strategic thinking with hands-on execution and problem solving - Communicates clearly and collaborates effectively across functions and external partners - Continuously challenges assumptions and looks for smarter, more scalable ways of working - Thrives in agile environments that require adaptability, rigor, and urgency - Highly organized, detail-oriented, and motivated by delivering high-quality outcomes that advance therapies for patients Annualized Base Salary $165,000—$185,000 USD ## Compensation & Benefits At Praxis, we believe that taking care of our people (and their people) is important, so we provide a world class benefits package to help you thrive.  This includes 99% of the premium paid for medical, dental and vision plans.  We also provide company-paid life insurance, AD&D, disability benefits, and voluntary plans to personalize your coverage. Thinking about the future?  We match dollar-for-dollar up to 6% on eligible 401(k) contributions and sweeten the deal with long-term stock incentives and ESPP.  We provide a discretionary quarterly bonus, an extremely flexible wellness benefit, generous PTO, paid holidays and company-wide shutdowns.  Not to mention, you'll also be joining a phenomenal crew of colleagues who are smart, engaged and inspiring.  We aim high, collaborate hard, and produce results.  Let’s achieve the impossible together! Company Overview Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance.  At Praxis we share a common vision of reshaping the human condition into a more freeing and fulfilled existence by developing high impact medicines for patients and families affected by and living with complex brain disorders.  Our core Values of Trust, Ownership, Curiosity and Results are foundational to every aspect of our business and are exemplified by each and every one of our team members. Diversity, Equity & Inclusion Guided by our core values, at Praxis Precision Medicines, Inc. we continue to DARE FOR MORE® to advance, promote, and champion diversity, equity, and inclusion by encouraging individuals to bring their authentic selves and perspectives to work each day. We are an equal opportunity employer and committed to providing opportunities to all qualified applicants without regard to race, religious creed, color, gender identity or expression, age, national origin, sexual orientation, disability, genetics, military service and veteran status, or any other characteristic protected by federal, state, or local laws. Attention: Job Scam Alert Praxis has recently become aware of fraudulent job recruitment postings from individuals claiming to represent Praxis. These postings seek financial information in connection with fraudulent opportunities for employment. If you suspect any fraudulent activity or misrepresentation in connection with a Praxis job opportunity, please report it to careers@praxismedicines.com. Praxis does not accept unsolicited submissions from recruitment agencies for open positions. We ask all recruitment agencies to refrain from contacting any Praxis employee regarding any position. All unsolicited resumes submitted by recruitment agencies to any Praxis employee in any form or method will be deemed to be the property of Praxis, and Praxis explicitly reserves the right to hire those candidate(s) without any financial obligation to the recruitment agency. ## About Praxis Precision Medicines, Inc. ## Company Overview - **One-liner**: Praxis Precision Medicines is a fully integrated, clinical-stage biopharmaceutical company developing precision therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. - **Entity Type**: Public (NASDAQ: PRAX) - **Headquarters**: Boston, Massachusetts, United States - **Founded**: 2015 - **Founders**: Dr. Steven Petrou (Co-Founder and President of R&D) ## Core Business - **Primary Industry**: Biotechnology (CNS / Neuroscience) - **Target Customers**: Patients with rare and prevalent neurological disorders (e.g., essential tremor, developmental and epileptic encephalopathies, focal epilepsy); healthcare providers; payers. - **Mission / Purpose**: To translate genetic insights into the development of life-altering therapies for CNS disorders more effectively and efficiently. ## Products & Services Praxis operates two proprietary platforms and a pipeline of late-stage and early-stage programs: - **Cerebrum™ (Small Molecule Platform)**: Orally available precision therapies targeting ion channels and neuronal circuits. Key assets include: - **Ulixacaltamide**: A T-type calcium channel inhibitor for essential tremor (ET). NDA submission to the FDA expected by mid-February 2026. Breakthrough Therapy Designation. - **Relutrigine**: For SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEEs). NDA submission expected by mid-February 2026. Breakthrough Therapy Designation. Also in Phase 3 for broad DEEs. - **Vormatrigine**: A sodium-channel modulator for focal onset seizures (FOS). In Phase 3 trials (POWER1, POWER2). - **Solidus™ (Antisense Oligonucleotide Platform)**: For genetically defined CNS disorders. Key asset: - **Elsunersen**: An ASO designed to reduce SCN2A gene expression for early-seizure-onset SCN2A-DEE. In Phase 3 (EMBRAVE3). Orphan Drug Designation. - **Early-Stage Pipeline**: Preclinical candidates (PRAX-020, PRAX-080, PRAX-090, PRAX-100) targeting other genetic epilepsies and neurodevelopmental disorders. ## Market Standing - **Market Cap**: ~$156.0 million (as of mid-2026 data) [linkedin.com] - **Key Metric (Revenue/Funding)**: Annual revenue reported at ~$8.6M (pre-commercial stage). Pro forma cash, cash equivalents, and marketable securities stand at **$1.5 billion** following a public offering in January 2026 that raised ~$621 million [ir.praxismedicines.com]. - **Notable Investors/Partners**: Ionis Pharmaceuticals, Inc. (collaboration on elsunersen); RogCon, Inc. (license agreement). - **Growth Signals**: - Rapidly scaling headcount: 166 employees (+49.7% year-over-year) [linkedin.com]. - Transformation to a commercial-stage company: Preparing for two NDA submissions by mid-February 2026. - Combined peak revenue estimates for its four late-stage assets expected to exceed **$20 billion** [ir.praxismedicines.com]. - Active hiring: 31 open positions in mid-2026 (up 933% year-over-year) [linkedin.com]. ## Competitive Advantages - **Precision Neuroscience Moat**: Deep understanding of shared biological targets and circuits in the brain derived from genetic epilepsies. - **Proprietary Dual Platforms**: Leveraging both small molecule (Cerebrum) and ASO (Solidus) modalities to address a wide range of CNS disorders. - **Breakthrough Therapy Designations**: Both lead assets (ulixacaltamide, relutrigine) have FDA Breakthrough Therapy Designation, accelerating development and review. - **Strong Cash Position**: $1.5 billion pro forma cash provides a long runway through multiple potential product launches and pipeline expansion. - **Late-Stage Pipeline**: Four late-stage product candidates approaching potential commercial launch, de-risking the company substantially. ## Strategic Focus - **Commercial Launch Readiness**: Building out commercial infrastructure, sales force, and patient support programs in parallel with regulatory submissions. - **Pipeline Expansion**: Declaring multiple new drug candidates from both Cerebrum and Solidus platforms in 2026. - **Lifecycle Management**: Exploring indication expansion for existing assets (e.g., relutrigine in broad DEEs via the EMERALD study; vormatrigine for monotherapy FOS). - **Global Reach**: Operating in 5 countries (US, Australia, India, Colombia, Brazil) with a growing workforce. ## Why Work Here - **Mission-Driven Work**: Opportunity to deliver transformative therapies to patients with severe, underserved CNS disorders. - **Growth Trajectory**: The company is at a pivotal inflection point, transitioning from a clinical-stage to a commercial-stage organization — offering dynamic career growth. - **Remote-First Culture**: The vast majority of open positions across all departments (Clinical, Medical, Commercial, Finance, Legal, etc.) are listed as **"United States - Remote"** [greenhouse.io]. This includes roles like Director, Commercial Compliance; Senior Clinical Trial Manager; and Director, Field Reimbursement. - **Global Talent**: Engineering and technical roles are open internationally (e.g., Software Engineer in Brazil) [greenhouse.io]. - **Strong Leadership**: Recent appointments of experienced pharmaceutical executives (Jeffrey B. Kinder, Stuart Arbuckle) and internal promotions (Megan Sniecinski to COO). - **Compensation**: Employee reviews indicate a strong **Compensation rating of 4.0/5.0**, though overall culture and career ratings are lower (2.8 and 2.7 respectively on LinkedIn) [linkedin.com]. - **Workforce Demographics**: A high proportion of Director-level roles are open (20% of workforce), alongside specialists and senior IC roles, suggesting significant opportunities for leadership-level hires. ## Sources 1. [greenhouse.io](http://job-boards.greenhouse.io/praxisprecisionmedicines) - Jobs at Praxis Precision Medicines, Inc. 2. [ir.praxismedicines.com](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-enters-its-next-chapter-following) - Press Release: Business Outlook and Priorities for 2026 3. [linkedin.com](https://www.linkedin.com/company/praxis-precision-medicines-inc) - LinkedIn Company Profile 4. [stockanalysis.com](https://stockanalysis.com/stocks/prax/company/) - Company Profile & Key Executives ## Other roles at Praxis Precision Medicines, Inc. - [Associate Director, Regulatory Affairs, AD Promo](https://feeny.ai/job/associate-director-regulatory-affairs-ad-promo-praxis-precision-medicines-inc-knjtsbdgq5rn) — United States - [Medical Information Specialist](https://feeny.ai/job/medical-information-specialist-praxis-precision-medicines-inc-united-states-p7f0w7ye8d61) — United States - [Clinical Medical Monitor](https://feeny.ai/job/clinical-medical-monitor-praxis-precision-medicines-inc-united-states-aycaavkze79q) — United States - [Manager, Analytical Sciences - Commercial](https://feeny.ai/job/manager-analytical-sciences-commercial-praxis-precision-medicines-inc-united-fj5ctas3k0w2) — United States - [Director, Medical Science Liaisons](https://feeny.ai/job/director-medical-science-liaisons-praxis-precision-medicines-inc-united-states-bhakzbah9dvw) — United States - [Associate Director, Regulatory CMC](https://feeny.ai/job/associate-director-regulatory-cmc-praxis-precision-medicines-inc-united-states-e2y1dazam5bd) — United States - [Computer Systems Validation Engineer](https://feeny.ai/job/computer-systems-validation-engineer-praxis-precision-medicines-inc-united-84kqsazb917h) — United States - [Clinical Development Leader, Lifecycle Management](https://feeny.ai/job/clinical-development-leader-lifecycle-management-praxis-precision-medicines-inc-hvv6gtsjkytp) — United States - [Clinical Development Leader, Epilepsies](https://feeny.ai/job/clinical-development-leader-epilepsies-praxis-precision-medicines-inc-united-ywq6h858ygqj) — United States - [Clinical Development Leader, Movement Disorders](https://feeny.ai/job/clinical-development-leader-movement-disorders-praxis-precision-medicines-inc-ysgcsw94ftfc) — United States